Clinical trial
A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer
NCT00092924 is registered in ClinicalTrials.gov with Human Genome Sciences Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer
- Lead sponsor
- Human Genome Sciences Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- March 31, 2005
- Enrollment
- Not reported
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.